Accelerating Innovation at Leica Biosystems

Capacity Accelerating Performance at IDT KEY PRIORITIES AT ACQUISITION Geographic +500bps Expansion Scale & INCREASE IN NON-US REVENUE AS % OF TOTAL SINCE ACQ. ADDITIONAL SQ FT OF +60K MANUF. SPACE TO SUPPORT CUSTOMER GROWTH RESULTS SINCE ACQUISITION XXXIDT INTEGRATED DNA TECHNOLOGIES 2018* 2021E Annual Revenue ~$300M >$500M Core Growth High-teens >20% Expansion Gross Margin ~60% >65% Commercial +50% AVG ANN. GROWTH NGS REV.: Cumulative OMX >750bps +50% NEW PRODUCTS, FUNNEL MGT. Execution & DAILY MGT. ROIC +HSD HOW QUALITY&TURN- WE WIN AROUND TIME CADENCE OF INNOVATION FLEXIBILITY & SCALABILITY *Inclusive of periods prior to Danaher ownership Driving results using Danaher LS scale and DBS-led execution DANAHER

View entire presentation